Portal:CPTAC/Hallmark/Proliferative

From WikiPathways

(Difference between revisions)
Jump to: navigation, search
(added pathway)
Current revision (00:11, 11 October 2019) (view source)
(removed main pathway models)
 
Line 6: Line 6:
*[[Pathway:WP382]] MAPK Signaling Pathway
*[[Pathway:WP382]] MAPK Signaling Pathway
*[[Pathway:WP4223]] Ras Signaling
*[[Pathway:WP4223]] Ras Signaling
-
*[[Pathway:WP2828]] Bladder Cancer
 
*[[Pathway:WP4205]] MET in type 1 papillary renal cell carcinoma
*[[Pathway:WP4205]] MET in type 1 papillary renal cell carcinoma
-
*[[Pathway:WP4255]] Non-small cell lung cancer
 
-
*[[Pathway:WP4263]] Pancreatic adenocarcinoma pathway
 
-
*[[Pathway:WP4155]] Endometrial cancer
 
*[[Pathway:WP313]] Signaling of Hepatocyte Growth Factor Receptor
*[[Pathway:WP313]] Signaling of Hepatocyte Growth Factor Receptor
*[[Pathway:WP4553]] FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma
*[[Pathway:WP4553]] FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma
*[[Pathway:WP4566]] Translation inhibitors in chronically activated PDGFRA cells
*[[Pathway:WP4566]] Translation inhibitors in chronically activated PDGFRA cells
*[[Pathway:WP4541]] Hippo-Merlin Signaling Dysregulation
*[[Pathway:WP4541]] Hippo-Merlin Signaling Dysregulation

Current revision

The normal control of cell growth and division in cells is governed by careful control and release of growth-promoting signals, but in cancer cells this control is deregulated. Signaling through growth factors via the tyrosine kinase domains of cell-surface receptors, trigger progression through the cell cycle and other pathways. (Adapted from Hallmarks of cancer: the next generation, Hanahan and Weinberg, Cell 2011)